Xanadu Bio
Xanadu Bio develops next-generation drug delivery systems utilizing the novel, tunable PACE polymer family for encapsulating and transporting nucleic acid payloads like mRNA. This platform is engineered for organ-specific targeting and immune-silent performance, mitigating toxicity associated with previous polymer nanoparticles. The company is applying this technology to create novel nucleic acid therapies in oncology and immunology, including intranasal vaccines for respiratory pathogens.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$12MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Xanadu Bio develops next-generation drug delivery systems utilizing the novel, tunable PACE polymer family for encapsulating and transporting nucleic acid payloads like mRNA. This platform is engineered for organ-specific targeting and immune-silent performance, mitigating toxicity associated with previous polymer nanoparticles. The company is applying this technology to create novel nucleic acid therapies in oncology and immunology, including intranasal vaccines for respiratory pathogens.